James H. Stanker's Insider Trades & SAST Disclosures
James H. Stanker's most recent trade in Processa Pharmaceuticals Inc was a trade of 3,077 Restricted Stock Units done . Disclosure was reported to the exchange on April 5, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern James H. Stanker.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 3,077 | 26,470 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 2,307 | 28,777 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 1,675 | 6,638 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 644 | 6,764 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.79 per share. | 05 Apr 2024 | 518 | 6,120 | - | 2.8 | 1,445 | Common Stock |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 385 | 29,162 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 385 | 29,547 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.71 per share. | 05 Apr 2024 | 282 | 6,482 | - | 1.7 | 482 | Common Stock |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 1,675 | 24,037 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 1,675 | 6,638 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.79 per share. | 01 Jan 2024 | 518 | 6,120 | - | 2.8 | 1,445 | Common Stock |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.80 per share. | 09 Feb 2023 | 12,500 | 61,750 | - | 0.8 | 10,000 | Common Stock |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 96,150 | 518,431 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 69,667 | 422,281 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 12,951 | 352,614 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 12,950 | 339,663 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 7,601 | 51,712 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 05 Aug 2022 | 2,462 | 49,250 | - | 3.2 | 7,805 | Common Stock |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 23,947 | 326,713 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 247,841 | 302,766 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 6,024 | 6,024 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2021 | 7,601 | 44,111 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2021 | 12,858 | 12,858 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2021 | 8,572 | 8,572 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2021 | 1,907 | 10,034 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.81 per share. | 21 Jun 2021 | 1,000 | 36,510 | - | 6.8 | 6,810 | Common Stock |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,127 | 8,127 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James H. Stanker | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 01 Oct 2020 | 6,000 | 47,248 | - | 4 | 24,000 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges